Sunday, May 31 | 8:00 AM - 11:30 AM
|
Lymphoma and Plasma Cell Disorders
| | | Session Type: Poster Session | | Track(s): Lymphoma and Plasma Cell Disorders | | Presentation(s): |
Abstract #8520
Interim analysis of a phase I study of INCB040093, a PI3Kd inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor, in patients (pts) with relapsed or refractory (r/r) B-cell malignancies.
Tycel Jovelle Phillips, MD
University of Michigan
|
Abstract #8558
A phase 1 study of INCB040093, a PI3Kd inhibitor, alone or in combination with INCB039110, a selective JAK1 inhibitor: Interim results from patients (pts) with relapsed or refractory (r/r) classical Hodgkin lymphoma (cHL).
Andres Forero-Torres, MD
University of Alabama at Birmingham
|
Can't find anything for the IDO/Yervoy combo. A late breaker, perhaps.? Only one abstract title for indoximod, NewLink's ido inhibitor.
Cheers, Tuck |
